Aurinia Pharmaceuticals (NASDAQ:AUPH) Cut to “Hold” at Bloom Burton

Bloom Burton cut shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a moderate buy rating to a hold rating in a report published on Wednesday,Zacks.com reports.

A number of other equities analysts have also weighed in on the company. Royal Bank Of Canada reissued a “sector perform” rating and issued a $15.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $17.67.

Aurinia Pharmaceuticals Stock Performance

AUPH stock opened at $14.61 on Wednesday. The stock’s 50 day simple moving average is $12.28 and its 200 day simple moving average is $10.17. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals has a 12-month low of $6.55 and a 12-month high of $16.20. The stock has a market capitalization of $1.92 billion, a PE ratio of 33.98 and a beta of 1.30.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.07. The firm had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Aurinia Pharmaceuticals will post 0.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its position in shares of Aurinia Pharmaceuticals by 21.7% in the third quarter. JPMorgan Chase & Co. now owns 533,290 shares of the biotechnology company’s stock worth $5,893,000 after purchasing an additional 94,941 shares during the period. Baader Bank Aktiengesellschaft bought a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at $344,000. Navellier & Associates Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at $926,000. State of Wyoming lifted its stake in shares of Aurinia Pharmaceuticals by 33.2% during the 3rd quarter. State of Wyoming now owns 37,702 shares of the biotechnology company’s stock valued at $417,000 after buying an additional 9,396 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in Aurinia Pharmaceuticals by 6.7% in the 3rd quarter. Principal Financial Group Inc. now owns 80,740 shares of the biotechnology company’s stock worth $892,000 after buying an additional 5,074 shares during the period. 36.83% of the stock is owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.